Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stella PharmaTSE:4888 +3.37%76 3-Year ROIIC % is 27.13 as of Mar. 2026, which is 47% above its 10-year median of 18.46. GuruFocus rates TSE:4888 with a GF Score™ of 76/100 and a GF Value™ of 円338.82 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,320 Biotechnology companies, Stella Pharma ranks better than 67.5% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Stella Pharma's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 27.13%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Stella Pharma's 3-Year ROIIC % or its related term are showing as below:
TSE:4888's 3-Year ROIIC % is ranked better than 67.5% of 1320
companies
in the Biotechnology industry
Industry Median: -4.82
vs TSE:4888: 27.13
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Stella Pharma 3-Year ROIIC % Related Terms
Stella Pharma 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Stella Pharma's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4888 vs VRTX, REGN, RVMD: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Stella Pharma's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stella Pharma 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stella Pharma's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Stella Pharma's 3-Year ROIIC % falls into.
Stella Pharma's 3-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -748.957 (Mar. 2026) - -806.775 (Mar. 2023) )
/
( 1580.394 (Mar. 2026) - 1367.294 (Mar. 2023) )
=
57.818
/
213.1
=
27.13%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Stella Pharma (TSE:4888) has a 3-Year ROIIC % of 27.13 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Stella Pharma and its competitors. This is 47% above median its historical median of 18.46. According to the industry distribution chart, Stella Pharma ranks #429 out of 1320 companies in the Biotechnology industry, placing it in the top 32.5%.
Is Stella Pharma's 3-Year ROIIC % too high?
Stella Pharma's current 3-Year ROIIC % of 27.13 is 47% above median its 10-year median of 18.46. Based on the distribution chart, Stella Pharma ranks #429 out of 1320 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Stella Pharma has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Stella Pharma's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Stella Pharma ranks #429 out of 1320 companies for 3-Year ROIIC %. This puts Stella Pharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Stella Pharma and its competitors. Stella Pharma's current 3-Year ROIIC % is 27.13, which is 47% above median its own 10-year median of 18.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stella Pharma stock overvalued right now?
Based on GuruFocus' analysis, Stella Pharma (TSE:4888) is currently considered Fairly Valued. The stock's GF Value™ is 円338.82, compared to a current price of 円307.00 — trading 9.4% below its estimated fair value. The current 3-Year ROIIC % is 27.13, which is 47% above median its 10-year median of 18.46. Stella Pharma's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Stella Pharma (TSE:4888), the current 3-Year ROIIC % is 27.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stella Pharma (TSE:4888) Overvalued in 2026?
Based on GuruFocus' analysis, Stella Pharma stock appears to be undervalued.
The current stock price of 円307.00 is trading 9.4% below its estimated GF Value™ of 円338.82.
GuruFocus considers Stella Pharma to be Fairly Valued.
Key valuation signals for TSE:4888:
3-Year ROIIC %: 27.13 (47% above median its 10-year median of 18.46)
GF Value™: 円338.82 vs. price of 円307.00 (9.4% below fair value)
No single metric tells the full story. See the TSE:4888 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stella Pharma Corp is a therapeutic drug research and development company. It is focused on the development of boron compounds, particularly used in boron neutron capture therapy (BNCT). The BNCT is a form of cancer radiation therapy for destroying cancer cells.
76GF Score
Get the complete analysis for TSE:4888
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4888 has been successfully added to your 
